다이노나 For Your Healthy Life – DiNonA

Greetings from CEO

Corporation overview

History

2019~2016 2019~2016
2015~2014 2015~2014
2013~2012 2013~2012
2011~2007 2011~2007
2006~1999 2006~1999

2019~2016

  • 2016. 11 4 different novel humanized antibodies patents application
    2016. 12 Nomination of the family company of KRIBB
    2016. 12 Confirmation of Rheumatoid arthritis efficacy of Immune modulating Ab in CIA monkey model
  • 2017. 08 Strategic alliance with Shanghai OPM Biosciences Co., Ltd. of China
  • 2018. 02 400 billion won-size Licensing Deal with Aprogen KIC. 4 programs (DNP001, DNP004, PD-1 Ab. And CD47 Ab.) were licensed-out
    2018. 05 Listing on KONEX (Korea New Exchange) market
    2018. 10 Nomination as a new candidate (H2319, DNP002) on National Onco-Venture (NOV)
  • 2019. 03 Research collaboration agreement with EpimAb Biotherapeutics in China on development of bispecific antibody candidates
    2019. 06 Research collaboration agreement with Harbour BioMed in China on development of fully antibody candidates

2015~2014

  • 2014. 03 Contract of organizer change to Korea Investment Co., Ltd.
    2014. 05 Clinical phase 1 examination initiation (ASAN Medical Center)
    2014. 07 Licensing agreement with China 3S bio company
    2014. 09 KDDF leukemia therapeutic antibody clinical phase 1 selected (4 billion won)
    2014. 09 Head office and lab moved to ASAN Medical Center Asan institute for life sciences
  • 2015. 05 Immune regulation antibody primates 6 months ADA suppress result secured
    2015. 06 Subject of breast cancer antibody drug of future industry led by technology development work selected (2.2 billion won)
    2015. 07 Thesis of lung cancer antibody drug published

2013~2012

  • 2012. 02 Medical device approved by China’s food and drug organization
    2012. 06 Monkey experiment of homogeneous organ transplant (Islet) and homogeneous organ transplant (kidney) initiation
  • 2013. 02 Non-clinical subject of KDDF homogeneous islet transplant selected (4.4 billion won)
    2013. 06 Completion of non-clinical antibody treatment of leukemia
    2013. 12 Immune regulation antibody & Leukemia therapeutic antibody patent
    2013. 12 Ministry of Health and Welfare level 2 Bio xeno-transplantation development agency xeno-islet transplantation subject selected (Seoul National University 2.2 billion won)
    2013. 12 Leukemia therapeutic antibody clinical phase 1 IND approved (Korean Food and Drugs Administration

2011~2007

  • 2007. 05 Transfer of medical device business agreement with TNL Inc.
    2007. 05 Establishment of laser medical device department
  • 2009. 10 Progress of leukemia therapeutic antibody preclinical trials
  • 2011. 01 Sixth progress of immune regulation antibody animal (monkey) testing
    2011. 10 Journal of Experimental Medicine (U.S Experimental medicine journal) thesis published and press release of immune suppression antibody
    2011. 10 Immune regulation antibody (MD-3) technology transfer agreement with Seoul National University R&D foundation

2006~1999

  • 1999. 02 Foundation of DiNonA Inc.
    1999. 08 Confirmation of venture business
  • 2001. 04 Foundation of company affiliated lab
    2001. 08 Selected as INNO-BIZ company
  • 2003. 07 Establishment of diagnostic reagent department
  • 2005. 08 Transfer of technology agreement about acute leukemia with Seoul National University R&D foundation
    2005. 09 License agreement about acute leukemia with the Arana (U.S and Australia)
    2005. 11 License agreement about acute leukemia with Kwang Dong Pharmaceutical Co., Ltd.

Locations

Head office

  • Adress : Asan institute for Life Sciences 11th floor, 88, Olympic-ro 43 gil, Songpa-gu, Seoul, Korea
  • Phone : +82-2-578-0810
  • Fax : +82-2-579-8552

Branch office

  • Address : 992, Honam-ro, Geumma-myeon, Iksan-si, Jeollabuk-do, Korea
  • Phone : +82-63-838-1701
  • Fax : +82-63-838-1710
TOP